Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Liver function test abnormal? 609 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 609 reports of Liver function test abnormal have been filed in association with INFLIXIMAB (Renflexis). This represents 0.4% of all adverse event reports for INFLIXIMAB.

609
Reports of Liver function test abnormal with INFLIXIMAB
0.4%
of all INFLIXIMAB reports
6
Deaths
100
Hospitalizations

How Dangerous Is Liver function test abnormal From INFLIXIMAB?

Of the 609 reports, 6 (1.0%) resulted in death, 100 (16.4%) required hospitalization, and 187 (30.7%) were considered life-threatening.

Is Liver function test abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 609 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Liver function test abnormal?

METHOTREXATE (1,416) ETANERCEPT (1,013) ADALIMUMAB (879) ATORVASTATIN (579) TOCILIZUMAB (526) LEFLUNOMIDE (489) ACETAMINOPHEN (465) TOFACITINIB (436) ABATACEPT (431) HYDROXYCHLOROQUINE (429)

Which INFLIXIMAB Alternatives Have Lower Liver function test abnormal Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Liver function test abnormal Reports All Drugs Causing Liver function test abnormal INFLIXIMAB Demographics